Ep 20. Sec. Alex Azar; Axios Investigates

In season 3 episode 20 of Axios, titled "Sec. Alex Azar; Axios Investigates," the show explores the current state of the U.S. health care system through in-depth interviews with top government officials and investigative reporting.

The episode features an interview with Secretary of Health and Human Services Alex Azar, who discusses the Trump administration's efforts to expand access to affordable health care and lower prescription drug prices. Azar also touches on the impact of COVID-19 on the health care industry and the government's response to the pandemic.

Axios Investigates segment delves into the issue of surprise medical billing, a controversial issue that has come under scrutiny in recent years. The report examines the practice of health care providers charging patients for services that they did not expect to receive or did not know were not covered by their insurance. The segment looks at the impact of surprise medical billing on patients and insurance companies and how the government is working to address the issue.

Another investigative report focuses on the opioid epidemic in the United States and the role of pharmaceutical companies in fueling the crisis. The report looks at the ongoing legal battles against major pharmaceutical companies and their alleged role in downplaying the addictive properties of opioids and encouraging doctors to prescribe them.

Throughout the episode, hosts Jim VandeHei, Mike Allen, and Jonathan Swan provide their own insights and analysis on the topics discussed. They also bring on guests, including health care experts and government officials, to provide additional context and perspective on the issues at hand.

Overall, "Sec. Alex Azar; Axios Investigates" offers a comprehensive look at some of the most pressing issues facing the U.S. health care system today. The episode sheds light on the government's efforts to address these issues and the ongoing challenges faced by patients, health care providers, and insurance companies.